E pEndymomas are the most common intramedullary spinal tumor, representing 15% of all spinal cord tumors and 60% of all spinal cord malignancies. 4, 7 Myxopapillary ependymomas represent a morphological variant of ependymomas that occur mostly in the lumbosacral/cauda equina area of the spinal cord.
Given the controversy regarding the use of adjuvant RT in the management of spinal MPE, a retrospective study was performed at our institution to assess the role of RT in the management of this disease.
Methods
Thirty-seven patients with histologically confirmed spinal MPEs treated between 1974 and 2007 were identified from a database approved by our institutional review board. Information was obtained through paper charts, electronic medical records, and radiographic images, and was entered into the database. The following data were collected for each patient: age at diagnosis, presenting symptoms, date of initial diagnosis, date of surgery (both at initial diagnosis and for subsequent recurrences), extent of surgeries, RT parameters (dose and fractionation), date(s) of recurrence, KPS score at time of treatment, and date of death or last follow-up. All tumors were addressed surgically with the same aggressive attempt at GTR. The extent of resection was defined as GTR, STR or biopsy, or unknown. Resections were piecemeal, given the difficulty in removing these in an en bloc fashion. In all of the cases, the extent of resection was defined by intraoperative evaluation. In some cases, postoperative imaging may confirm the extent of resection; however, given the possible postoperative changes seen on MR imaging, it was thought that intraoperative evaluation was more reliable for this study. Some patients were also treated prior to the era in which MR imaging was being used routinely. For fair comparisons of patients over the decades that they were treated, it was decided to define the extent of resection by using the intraoperative evaluation. Radiation was delivered via an external-beam approach. Techniques included posterior-anterior only, 3D conformal therapy, intensity-modulated RT, and spine stereotactic radiosurgery. If patients did not receive RT up front, they were considered for this therapy versus repeat resection at the time of recurrence. Recurrence was defined as progression on imaging studies from either a CT or MR imaging session. Side effects from RT were also recorded.
Statistical Analysis
Kaplan-Meier analyses and Cox proportional hazard regression were used to determine what patient and treatment factors influenced OS and recurrence. These end points were assessed for patients undergoing up-front treatment and first salvage treatment.
Results
The median age and KPS score at the time of initial diagnosis was 33 years and 80, respectively. The median follow-up time was 4.4 years (range 0.1-22.5 years). The most common presenting symptom was pain, occurring in 86.5% of patients. All patients received surgery as their initial treatment. Nine patients also received RT along with their surgery, with a median total dose of 50.2 Gy (range 45-58 Gy). The RT data in 1 of these patients were unknown. Tables 1 and 2 summarize the patient characteristics and treatment. The mean survival time was 12 years, and only 4 of 37 patients had died at the time of this study. In 3 of the 4 cases the cause of death was unknown but was not believed to be due to tumor recurrence. In the fourth case, the exact cause of death was also unknown but was probably due to surgical complications, because the patient died approximately 1.5 months after surgery for recurrence. None of the patient or treatment parameters significantly correlated with OS. Figure 1 and Table 3 summarize these results for OS.
Sixteen patients (43.2%) were found to have a recurrence, with a median time to recurrence of 7.7 years (Fig.  2) . None of the patient or treatment parameters correlated with RFS for an initial recurrence. Gross-total resection ( Fig. 3 ) and adjuvant RT (Fig. 4) were associated with better RFS rates, with neither being statistically significant. Table 4 shows that no patient or treatment factors were significant for predicting an initial recurrence for selected patient and treatment characteristics. Table 5 summarizes the median RFS for first recurrence. At the time of initial recurrence, 10 of these 16 patients received only surgery, 3 received both surgery and RT, and 3 received only RT as salvage treatment. The median RT dose was 50.4 Gy (range 45-54 Gy).
Of the 16 patients with recurrent MPE, 9 (56.3%) were found to have a second recurrence, at which point they underwent the following treatments: 5 had surgery only, 2 had surgery and RT, 1 had RT only, and 1 had no additional therapy. The median time to this second recurrence was 1.6 years.
The use of RT as salvage therapy after the initial recurrence significantly correlated with longer times to a second recurrence. The median RFS time for a second recurrence for those who received RT was 9.6 years versus 1.1 years for those who did not receive RT (p = 0.0093, log-rank test; Fig. 5 ). None of the other parameters significantly correlated with a second recurrence. Table 6 summarizes these results.
Of the patients receiving any RT, 2 developed transient weakness, 2 developed nausea and vomiting, and 1 developed a transient decrease in leg coordination. Nevertheless, RT was generally well tolerated.
Discussion
Given the controversies in the management of spinal MPE, we reviewed our institutional experience to help determine the optimal management of spinal MPE. Thirty-seven patients with histologically verified spinal MPE were found in our database, making this series one of the largest at a single institution reported to date. At presentation, GTR was suggestive of improved RFS, but given the small number of patients, this was not statis- tically significant. A larger cohort may show this to be the case. Up-front RT did not improve RFS. Based on our institutional practice, given the long natural history of this tumor and the lack of clear evidence, 6 of 8 patients with known STR or biopsy received no additional adjuvant therapy. The extent of resection did not increase the likelihood of receiving adjuvant RT. It is important to note that this study, like many others described below, has a small number of patients and may be underpowered to detect a difference in RFS for up-front RT. Also, given the small numbers, we caution against strictly interpreting these data but urge practitioners to consider all available studies in formulating treatment decisions. These studies will be discussed later. At the time of recurrence, however, the use of RT provided the most benefit in preventing a second recurrence. Those who did not receive RT had a median time to second recurrence of 1.1 years; however, those who received this therapy had a median time to second recurrence of 9.6 years (p = 0.0093). Radiation therapy at second recurrence appears to have the most benefit in preventing another relapse. Again, given the small numbers, this needs to be interpreted with caution; however, the results are consistent with what is known about the natural history of this tumor from other institutions.
In comparison, in 2006 Akyurek et al. 1 reviewed 35 charts of patient with spinal MPE from the M. D. Anderson Cancer Center. These investigators evaluated local control, PFS, and OS for those patients who underwent GTR or STR alone versus those who underwent GTR or STR with adjuvant RT. All of their patients received surgery as an initial treatment for their diagnosis. Radiation therapy was given adjuvantly to 63% of their patients, with a median dose of 50.4 Gy and a median dose per fraction of 1.8 Gy. Their results showed that there was no statistical difference for OS or PFS in relation to the extent of initial surgery. However, the use of adjuvant RT, regardless of the extent of surgery, resulted in better local control rates and PFS at 10 years than either GTR or STR alone. The 5-and 10-year PFS rates for patients who received adjuvant RT were 82% and 75%, respectively, versus surgery alone, at 49% and 37%, respectively (p = 0.04). The 10-year local control rates with or without adjuvant RT were 86% and 46%, respectively (p = 0.03). The Recurrence-free survival after initial surgery for 37 patients with MPE. Fig. 3 . Recurrence-free survival after initial surgery for 34 patients with MPE, categorized by extent of resection (p values were calculated using the log-rank test). mst = mean survival time; n = number. Fig. 4 . Recurrence-free survival after initial surgery for 37 patients with MPE who received adjuvant RT (p values were calculated using the log-rank test).
10-year OS for all patients was 97%. These numbers are consistent with our data, although their study did show a statistical benefit to up-front RT. It is important to note that the 5-and 10-year PFS rates for surgery alone are fairly high. Many of these patients continue to have stable disease even 10 years out, without up-front RT.
In a separate paper by Gomez et al. 2 published in 2005, a similar study was performed in patients treated for spinal ependymomas, regardless of subtype, at UCSF. These authors studied 37 patients with spinal ependymomas, 7 of which were MPEs, and focused on several parameters, including the total radiation dose and the extent of initial surgery. Their goal was to assess the local control rates and PFS at 5, 10, and 15 years, as well as correlate prognostic factors such as the two listed above. They reported that only the extent of surgery was significantly correlated with the PFS (p = 0.006) and that RT was not correlated (p = 0.75). These results are different from the results from the M. D. Anderson Cancer Center data. They do include other subtypes, which may make interpreting these data specifically for spinal MPE difficult.
Volpp et al. 9 reported their experience from Kaiser Permanente in Los Angeles, California, treating 23 patients for intradural spinal cord ependymomas. Six patients had spinal MPE. Patients were treated between 1988 and 2000. Seventeen were treated with surgery alone; 5 received surgery and RT; and 1 received surgery, RT, and chemotherapy. They reported good outcomes regardless of treatment but suggested that patients undergoing STR should be considered for RT. Again, like Gomez et al., 2 other subtypes of ependymomas were included.
Wahab et al. 10 reviewed 22 patients treated between 1954 and 1997 for spinal canal ependymoma. Nine patients had a diagnosis of MPE. Twenty had STR, and the remainder had GTR. All patients received RT to a median dose of 45 Gy (range 30-54 Gy). The biggest determinant of recurrence was size in this study, with a 10-year PFS of 58.3% for tumors larger than 6 cm and 92.3% for tumors 6 cm or less. Radiation was found to be safe, with no identifiable long-term toxicity attributed to this treatment. No dose response was seen. Given the small sample size, these authors could not make conclusions regarding treatment variables.
The largest series is a multiinstitutional study from the Rare Cancer Network. This series of 85 patients showed that high-dose RT given postoperatively was an independent predictor of PFS on multivariate analysis. The 5-year PFS in this series for patients treated with postoperative RT was 78.4% versus 50.4% for surgery alone. 5 These are equivalent to our results. Again as noted, PFS for surgery alone is quite high.
In Table 7 we review selected series of patients and compare them with our results. Based on our data and the data of other institutions, spinal MPE typically has a long natural history, with slow growth. It remains difficult, however, to predict up front when or if a patient will suffer recurrence. When spinal MPE is allowed to take its course without adjuvant intervention, presumably this reveals those who may progress more rapidly. It is this group that benefits the most from adjuvant RT. This is consistent with the UCSF data, which showed no benefit to up-front RT.
The treatment of spinal MPE, especially in light of its long natural history, must be individualized, based on our data and the data from other institutions. Patients with STR or who are not receiving adjuvant RT have a median time to recurrence of 5.5 years. Factors to consider include potential deficits caused by more aggressive resection, age of the patient, deficits resulting from tumor involvement, the possibility of future resection should there be neurological progression, long-term effects from radiation, and the patient's wishes.
Conclusions
The optimal treatment of spinal MPE remains controversial. Based on our data, a less aggressive resection to maintain functionality and delaying RT at the time of recurrence is a reasonable approach. This may maximize patient quality of life by delaying any sequelae from aggressive surgery or side effects from radiation.
